Please assess the completion status of the following clinical trial:

Trial Title: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
MAIN STUDY~Inclusion Criteria:~* Male and female patients, age 21 to 60 with relapsing forms of MS, treated with natalizumab for 12 consecutive months or longer with anti-JCV Ab positive during that time period.~* Able to understand and sign Informed Consent Document.~* Stable disease during treatment with natalizumab. No clinical relapses for at least 12 months.~* Stable MRI on follow-up MRI scans for prior 12 months without evidence of new or enlarging T-2 hyperintensities or Gd+ lesions.~* No clinical evidence by imaging or cerebrospinal fluid (CSF) for PML.~* No evidence of significant cognitive limitation or psychiatric disorder.~* Expanded Disability Status Scale (EDSS) of 1.0 to 6.0 inclusive.~Exclusion Criteria:~* Any mental condition of such that patient is unable to understand the nature, scope and possible consequences of the study.~* Patients that are known HIV positive.~* Patients with a known history of hepatitis.~* Known history of active tuberculosis not adequately treated, or a positive ppd skin test or positive quantiferon gold.~* Any persistent or severe infection.~* Any malignancy within 5 years, except for Basal or Squamous cell skin lesions, which have been surgically excised, with no evidence of metastasis.~* Clinically relevant or unstable cardiovascular, neurological (i.e. progressive weakness, increasing hypesthesia), endocrine, or other major systemic diseases.~* History of drug or alcohol abuse within the past year.~* Any significant depression or psychiatric disease (BDI II greater than 25) within the past year.~* Any significant lab abnormality as deemed by the investigator including but not limited to the following:~  1. Hypoproteinemia with serum albumin \< 3.0g/dl.~ 2. Serum creatinine \>133umol/L (or \>1.5 mg/dl)~ 3. Hematocrit \<24% and/or~ 4. Absolute white blood cell count \< 4,000 cells/mm3 (µl) and/or~ 5. Platelet Count \<150,000 cells/mm3 (µl) and /or~ 6. Absolute neutrophil \< 1,500 cells/mm3 (µl)~ 7. Liver function impairment or persisting elevations of serum glutamate pyruvate transaminase (SGPT)/ Alanine transaminase (ALT), serum glutamate oxaloacetate transaminase (SGOT)/ aspartate aminotransferase (AST), or direct bilirubin greater than 1.5 fold the upper limit of normal.~* Any confounding illness or other diseases of the spine or bone that would impair evaluation of the patient or treatment effects.~* Any clinical, CSF or MRI evidence for PML.~* Prior treatment with immunosuppressive drugs except for past use of intravenous steroids to treat MS relapses.~* Pregnant or breast feeding women.~* Women of childbearing potential not protected by effective contraceptive method of birth control and/or are unwilling or unable to be tested for pregnancy.~* In the conception of a child during the course of the trial.~* Known history of hypersensitivity to teriflunomide or leflunomide.~* Persisting elevations (confirmed by retest) of serum amylase or lipase greater than 2-fold the upper limit of normal.~* Known history of chronic pancreatic disease or pancreatitis.~* Prior use within 4 weeks before randomization or concomitant use of phenytoin, warfarin, tolbutamide, cholestyramine, or products containing St. John's Wort~SUB-STUDY~Eligibility Criteria for JCV sub-study:~* Must have been enrolled in the SWITCH protocol and received at least 1 dose of 14mg TFM during the study period.~* Must be willing to sign written, informed consent for this JCV sub-study and follow protocol requirements.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide (Type: EXPERIMENTAL): Teriflunomide 14 mg oral teriflunomide daily

Based on this trial design, predict the completion outcome and termination type (if applicable).